Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay
Part of paid clinical trials in Boise, Idaho.
- Sponsor
- Sequenom, Inc.
- Study ID
- NCT02586389
- Status
- Recruiting
Conditions
- Non-hematologic Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
This specimen collection is designed to obtain whole blood and tumor tissue from subjects diagnosed with cancer for the purpose of the development of a noninvasive liquid biopsy assay using next generation sequencing (NGS).
Key Dates
- Start date
- Oct 13, 2015
- Status verified
- Oct 2024
- Primary completion
- Oct 31, 2027
- Completion
- Oct 31, 2027
Study Design
- Enrollment
- 3,000 participants (estimated)
Arms
- Arm: Non-hematological Cancer CohortEligible subjects will have been previously diagnosed with a non-hematological cancer with tumor present at baseline blood draw.
Primary Outcome Measure
biospecimen sample collection for liquid biopsy assay development [ Time Frame: After cancer diagnosis through 5 years of standard of care follow-up visits ]
Central Contacts
- Graham McLennan(858) 202-9162
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Idaho Urology | Boise | Idaho | - | - |
Find similar trials in Boise, ID
By research site